GlaxoSmithKline Coreg
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Long-term treatment with the beta blocker carvedilol can reduce the risk of a subsequent heart attack in post-MI patients by 41% and mortality by 23%, according to results of the 1,900-patient CAPRICORN (Carvedilol Post Infarction Survival Control in Left Ventricular Dysfunction) trial, presented March 20 at the 50th Annual Scientific Session of the American College of Cardiology. The trial evaluated the effect of carvedilol for a mean of 15 months in post-acute MI patients with left ventricular dysfunction who were already taking ACE inhibitors. GSK is considering filing an sNDA for use in MI patients with LVD who are receiving ACE inhibitor